In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

Tato, Marta; García-Castillo, María; Bofarull, Ana Moreno; Cantón, Rafael

doi:10.1016/j.ijantimicag.2015.07.004

Cited by 51 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MICs of both ceftazidime-avibactam and ceftolozanetazobactam were significantly higher as isolates became resistant to more ␤-lactams. These results corroborate recent reports of decreased susceptibility to ceftazidime-avibactam and ceftolozane-tazobactam among P. aeruginosa isolates that are resistant to other ␤-lactams, compared with isolates that are susceptible (3,(13)(14)(15). Taken together, the data demonstrate that ceftazidimeavibactam and ceftolozane-tazobactam are important additions to the antimicrobial armamentarium, but findings suggest that the agents will need to be used judiciously to preserve their activity.…”

supporting

confidence: 89%

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

Buehrle

Shields

Chen

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three ␤-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.

show abstract

supporting

confidence: 89%

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

Buehrle

Shields

Chen

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…In 10 patients (83.3%), microbiological eradication was observed 30 days after completion of treatment with C-T, which is similar to observations in previous studies (8). In these patients, the median duration of treatment with C-T was 14 days (range, 9 to 21).…”

supporting

confidence: 87%

“…C-T is a new combination of an antipseudomonal cephalosporin and a beta-lactamase inhibitor. The drug exhibits potent in vitro activity against MDRPA strains and other Gram-negative microorganisms, including extendedspectrum beta-lactamase-producing (ESBL) Enterobacteriaceae (although activity against ESBL Klebsiella is lower than that against other ESBL-producing Enterobacteriaceae) (7,8). The efficacy of C-T was evaluated in two pivotal phase III trials that resulted in the drug being approved for the treatment of complicated urinary tract infection, including acute pyelonephritis (9), and in the treatment of complicated intra-abdominal infections associated with metronidazole (10).…”

mentioning

confidence: 99%

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

Castón

Torre

Ruiz‐Camps

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.

show abstract

“…In vitro, it inhibits Ambler A class C (Amp C) enterobacteria and some class D enzymes (including OXA 48, except those produced by A Baumannii). Avibactam improves the activity of ceftazidime against ESBL-producing gram negative bacteria, carbapenemase type A (KPC), some type D (OXA) and class C of Ambler (AmpC) [11][12][13].…”

Section: Resultsmentioning

confidence: 99%

Colistin`S Dark Face. Resurrection of Polymyxin Antibiotics and Alternative Strategies

2017

JACCOA

View full text Add to dashboard Cite

Due to the lack of new antibiotics for the treatment of critically ill patients with multidrug-resistant bacteria, interest on "old" antibiotics like colistin (polymyxin E) re-emerged. This polymyxin has gained an important role as salvage therapy for patients infected with microorganisms susceptible only to colistin. It is important to know the dark face of colistin referring here to its important toxicity, often lethal, especially in critically ill patients. Given its rarity we briefly mentioned a case of profound encephalopathy in a post-surgical patient who recovered completely after stopping the drug. In addition, its variable pharmacokinetics make it very difficult to establish an effective regimen, most of which is infratherapeutic and with the limitation of its toxicity, which is a terrible problem for humanity. The common sense of the clinician and the birth of new antibiotics, as an alternative strategy, represent a hope to eradicate multiresistance.

show abstract

In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

Cited by 51 publications

References 21 publications

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

Colistin`S Dark Face. Resurrection of Polymyxin Antibiotics and Alternative Strategies

Contact Info

Product

Resources

About